Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Could a pill every other day be just as good for prostate symptoms?

NCT ID NCT07308002

Symptom relief Sponsor: Mansoura University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares taking tamsulosin every day versus every other day in 288 men aged 40 and older with enlarged prostate and moderate-to-severe urinary symptoms. The goal is to see if the every-other-day schedule controls symptoms just as well while possibly causing fewer sexual side effects. Participants will be followed for 24 weeks, and the main measure is change in urinary symptom scores.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
tamsulosin
What this could lead to
If successful, this could offer men with enlarged prostate a simpler, every-other-day dosing option that controls urinary symptoms just as well as daily pills, with fewer sexual side effects.
What could go wrong
This is a Phase 4 trial, but it hasn't started yet. The every-other-day regimen might not control symptoms as well as daily dosing, and results may not apply to all men with BPH.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 4

Runs after approval, following long-term safety and how well the treatment works in everyday use.

Participants

About 288 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jan 2026

An estimate. Start dates often move.

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * • Men ≥40 years with LUTS/BPH. * IPSS ≥8, Qmax 5-15 mL/s (voided volume ≥150 mL), PVR \<200 mL. * Sexually active within the past month (for ejaculatory outcomes). * BPH-treatment naïve: no prior use of antimuscarinics or 5-α-reductase inhibitors (5-ARIs) and agrees not to initiate these agents during the trial. Exclusion Criteria: * • PVR ≥ 200 mL. * Prior prostate/ radical pelvic surgery (that affect pelvic innervation). * Neurogenic bladder (atonic/ hypotonic bladder). * Severe hepatic/renal insufficiency. * Significant cardiovascular or cerebrovascular disease. * Any indication of surgical treatment (vesical stones, chronic urine retention, recurrent attacks of acute urine retention, recurrent attacks of gross hematuria, hydronephrosis)

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Lower urinary tract symptoms are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

benign prostatic hyperplasia Ejaculatory Dysfunction Lower Urinary Tract Symptoms urethral obstruction

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Lower urinary tract symptoms Prostate obstruction

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Urology and nephrology center

    Al Mansurah, Outside U.S./Canada, 35516, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.